Fri, Mar 22nd 2024
Biognosys sets a new standard in biomarker discovery with cutting-edge plasma proteomics, offering unparalleled depth and throughput.
Biognosys, a proteomics firm from Zurich, announced the enhancement of platform for plasma proteomics in drug discovery and development. According to this press release they have made advancements in a novel plasma enrichment method, marking a significant leap in proteome coverage, data quality, and research efficiency.
The upgraded platform now facilitates the analysis almost 7000 plasmas at once. The platform’s new deep high-throughput workflow allows for the profiling of up to 4,500 protein groups, catering to large-scale studies with unprecedented speed. The technique combines optimised machine learning-enhanced data analysis in to achieve this.
The method’s innovation potential is poised to render the plasma proteome fully actionable in extensive clinical studies, heralding a new era in biomarker discovery.
The TrueDiscovery® platform’s application extends beyond plasma and serum to various sample types, proteome coverage of over 13,000 proteins in tissues and over 10,000 proteins.
English 
German 
French 
Spanish 
Arabic 
